Comparison of the clinical performance and usefulness of five SARS-CoV-2 antibody tests.
We examined the usefulness of five COVID-19 antibody detection tests using 114 serum samples at various time points from 34 Japanese COVID-19 patients. We examined Elecsys Anti-SARS-CoV-2 from Roche, and four immunochromatography tests from Hangzhou Laihe Biotech, Artron Laboratories, Chil, and Nada...
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2021-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0246536 |
| _version_ | 1819111546677100544 |
|---|---|
| author | Mitsuru Wakita Mayumi Idei Kaori Saito Yuki Horiuchi Kotoko Yamatani Suzuka Ishikawa Takamasa Yamamoto Gene Igawa Masanobu Hinata Katsuhiko Kadota Taro Kurosawa Sho Takahashi Takumi Saito Shigeki Misawa Chihiro Akazawa Toshio Naito Takashi Miida Kazuhisa Takahashi Tomohiko Ai Yoko Tabe |
| author_facet | Mitsuru Wakita Mayumi Idei Kaori Saito Yuki Horiuchi Kotoko Yamatani Suzuka Ishikawa Takamasa Yamamoto Gene Igawa Masanobu Hinata Katsuhiko Kadota Taro Kurosawa Sho Takahashi Takumi Saito Shigeki Misawa Chihiro Akazawa Toshio Naito Takashi Miida Kazuhisa Takahashi Tomohiko Ai Yoko Tabe |
| author_sort | Mitsuru Wakita |
| collection | DOAJ |
| description | We examined the usefulness of five COVID-19 antibody detection tests using 114 serum samples at various time points from 34 Japanese COVID-19 patients. We examined Elecsys Anti-SARS-CoV-2 from Roche, and four immunochromatography tests from Hangzhou Laihe Biotech, Artron Laboratories, Chil, and Nadal. In the first week after onset, Elecsys had 40% positivity in Group S (severe cases) but was negative in Group M (mild-moderate cases). The immunochromatography kits showed 40-60% and 0-8% positivity in Groups S and M, respectively. In the second week, Elecsys showed 75% and 50% positivity, and the immunochromatography tests showed 5-80% and 50-75% positivity in Groups S and M, respectively. After the third week, Elecsys showed 100% positivity in both groups. The immunochromatography kits showed 100% positivity in Group S. In Group M, positivity decreased to 50% for Chil and 75-89% for Artron and Lyher. Elecsys and immunochromatography kits had 91-100% specificity. Elecsys had comparable chronological change of cut-off index values in the two groups from the second week to the sixth week. The current SARS-CoV-2 antibody detection tests do not provide meaningful interpretation of severity and infection status. Its use might be limited to short-term epidemiological studies. |
| first_indexed | 2024-12-22T03:59:20Z |
| format | Article |
| id | doaj.art-e9f4824746a743bdbc5c9aaf99c65e82 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-22T03:59:20Z |
| publishDate | 2021-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-e9f4824746a743bdbc5c9aaf99c65e822022-12-21T18:39:48ZengPublic Library of Science (PLoS)PLoS ONE1932-62032021-01-01162e024653610.1371/journal.pone.0246536Comparison of the clinical performance and usefulness of five SARS-CoV-2 antibody tests.Mitsuru WakitaMayumi IdeiKaori SaitoYuki HoriuchiKotoko YamataniSuzuka IshikawaTakamasa YamamotoGene IgawaMasanobu HinataKatsuhiko KadotaTaro KurosawaSho TakahashiTakumi SaitoShigeki MisawaChihiro AkazawaToshio NaitoTakashi MiidaKazuhisa TakahashiTomohiko AiYoko TabeWe examined the usefulness of five COVID-19 antibody detection tests using 114 serum samples at various time points from 34 Japanese COVID-19 patients. We examined Elecsys Anti-SARS-CoV-2 from Roche, and four immunochromatography tests from Hangzhou Laihe Biotech, Artron Laboratories, Chil, and Nadal. In the first week after onset, Elecsys had 40% positivity in Group S (severe cases) but was negative in Group M (mild-moderate cases). The immunochromatography kits showed 40-60% and 0-8% positivity in Groups S and M, respectively. In the second week, Elecsys showed 75% and 50% positivity, and the immunochromatography tests showed 5-80% and 50-75% positivity in Groups S and M, respectively. After the third week, Elecsys showed 100% positivity in both groups. The immunochromatography kits showed 100% positivity in Group S. In Group M, positivity decreased to 50% for Chil and 75-89% for Artron and Lyher. Elecsys and immunochromatography kits had 91-100% specificity. Elecsys had comparable chronological change of cut-off index values in the two groups from the second week to the sixth week. The current SARS-CoV-2 antibody detection tests do not provide meaningful interpretation of severity and infection status. Its use might be limited to short-term epidemiological studies.https://doi.org/10.1371/journal.pone.0246536 |
| spellingShingle | Mitsuru Wakita Mayumi Idei Kaori Saito Yuki Horiuchi Kotoko Yamatani Suzuka Ishikawa Takamasa Yamamoto Gene Igawa Masanobu Hinata Katsuhiko Kadota Taro Kurosawa Sho Takahashi Takumi Saito Shigeki Misawa Chihiro Akazawa Toshio Naito Takashi Miida Kazuhisa Takahashi Tomohiko Ai Yoko Tabe Comparison of the clinical performance and usefulness of five SARS-CoV-2 antibody tests. PLoS ONE |
| title | Comparison of the clinical performance and usefulness of five SARS-CoV-2 antibody tests. |
| title_full | Comparison of the clinical performance and usefulness of five SARS-CoV-2 antibody tests. |
| title_fullStr | Comparison of the clinical performance and usefulness of five SARS-CoV-2 antibody tests. |
| title_full_unstemmed | Comparison of the clinical performance and usefulness of five SARS-CoV-2 antibody tests. |
| title_short | Comparison of the clinical performance and usefulness of five SARS-CoV-2 antibody tests. |
| title_sort | comparison of the clinical performance and usefulness of five sars cov 2 antibody tests |
| url | https://doi.org/10.1371/journal.pone.0246536 |
| work_keys_str_mv | AT mitsuruwakita comparisonoftheclinicalperformanceandusefulnessoffivesarscov2antibodytests AT mayumiidei comparisonoftheclinicalperformanceandusefulnessoffivesarscov2antibodytests AT kaorisaito comparisonoftheclinicalperformanceandusefulnessoffivesarscov2antibodytests AT yukihoriuchi comparisonoftheclinicalperformanceandusefulnessoffivesarscov2antibodytests AT kotokoyamatani comparisonoftheclinicalperformanceandusefulnessoffivesarscov2antibodytests AT suzukaishikawa comparisonoftheclinicalperformanceandusefulnessoffivesarscov2antibodytests AT takamasayamamoto comparisonoftheclinicalperformanceandusefulnessoffivesarscov2antibodytests AT geneigawa comparisonoftheclinicalperformanceandusefulnessoffivesarscov2antibodytests AT masanobuhinata comparisonoftheclinicalperformanceandusefulnessoffivesarscov2antibodytests AT katsuhikokadota comparisonoftheclinicalperformanceandusefulnessoffivesarscov2antibodytests AT tarokurosawa comparisonoftheclinicalperformanceandusefulnessoffivesarscov2antibodytests AT shotakahashi comparisonoftheclinicalperformanceandusefulnessoffivesarscov2antibodytests AT takumisaito comparisonoftheclinicalperformanceandusefulnessoffivesarscov2antibodytests AT shigekimisawa comparisonoftheclinicalperformanceandusefulnessoffivesarscov2antibodytests AT chihiroakazawa comparisonoftheclinicalperformanceandusefulnessoffivesarscov2antibodytests AT toshionaito comparisonoftheclinicalperformanceandusefulnessoffivesarscov2antibodytests AT takashimiida comparisonoftheclinicalperformanceandusefulnessoffivesarscov2antibodytests AT kazuhisatakahashi comparisonoftheclinicalperformanceandusefulnessoffivesarscov2antibodytests AT tomohikoai comparisonoftheclinicalperformanceandusefulnessoffivesarscov2antibodytests AT yokotabe comparisonoftheclinicalperformanceandusefulnessoffivesarscov2antibodytests |